Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123


Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.

Chung Y, Chang JH, Kim BS, Lee JM, Kim HY, Kang CY.

Eur J Immunol. 2007 Jun;37(6):1453-62.


Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Gerner MY, Mescher MF.

J Immunol. 2009 Mar 1;182(5):2726-37. doi: 10.4049/jimmunol.0803479.


Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.

Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.

Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256.


Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

Tanaka Y, Koido S, Ohana M, Liu C, Gong J.

J Immunol. 2005 Feb 1;174(3):1274-80.


NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.

Stober D, Jomantaite I, Schirmbeck R, Reimann J.

J Immunol. 2003 Mar 1;170(5):2540-8.


Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.

Matthews KE, Qin JS, Yang J, Hermans IF, Palmowski MJ, Cerundolo V, Ronchese F.

J Immunol. 2007 Nov 1;179(9):5738-47.


DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.

Han WG, Schuurhuis DH, Fu N, Camps M, van Duivenvoorde LM, Louis-Plence P, Franken KL, Huizinga TW, Melief CJ, Toes RE, Ossendorp F.

Eur J Immunol. 2009 Jul;39(7):1765-73. doi: 10.1002/eji.200838842.


Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.

Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y.

Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8.


Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.

Mitsui H, Inozume T, Kitamura R, Shibagaki N, Shimada S.

J Invest Dermatol. 2006 Aug;126(8):1804-12. Epub 2006 Apr 27.


Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.

Ontiveros F, Wilson EB, Livingstone AM.

Immunology. 2011 Apr;132(4):549-58. doi: 10.1111/j.1365-2567.2010.03400.x. Epub 2011 Jan 24.


CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.

Serre K, Giraudo L, Siret C, Leserman L, Machy P.

Eur J Immunol. 2006 Jun;36(6):1386-97.


Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.

Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA.

Immunol Cell Biol. 2011 Nov;89(8):904-13. doi: 10.1038/icb.2011.13. Epub 2011 Mar 8.


Supplemental Content

Support Center